Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sinopharm Medicine To Launch IPO In Hong Kong

This article was originally published in PharmAsia News

Executive Summary

Sinopharm Medicine Holding, a core subsidiary of Sinopharm, will launch its initial public offering in Hong Kong soon, according to sources who disclosed that the firm has obtained approval from the authorities and will hold a public hearing next week. The official listing, targeted for late August or early September, is expected to raise up to RMB 7 billion ($1.02 billion). However, Sinopharm Medicine Holding denied the news, but said that it would likely restructure the pharmaceutical and trade business with another Sinopharm listed subsidiary Accord Pharm after the IPO if it occurs. The move is to boost the company's poor performance in retail drugstore business, which currently only accounts for 3.6 percent of its total revenue. (Click here for more - Chinese Language)

You may also be interested in...

Where The COVID Vaccine Trials Stand: A Snapshot Of The Leaders And Rest Of The Field

With some studies about to finish and others on clinical hold, the coronavirus vaccine field approaches an infection point as the US FDA prepares for its first advisory committee on the topic. Our charts and graphics offer a quick look at what stands where.

Neuromodulation Firm Lands €10.5M For Tinnitus Treatment

Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.

Reckitt Spies Opportunity For Global Supplements Business

RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts